ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $2.07 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-14.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-03-14
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2012 was $2.07M, a 8.32% decline from fiscal 2011.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2011 was $2.26M, a 1.76% decline from fiscal 2010.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2010 was $2.30M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $2.07M 10-K · filed 2013-03-14 |
| 2011-12-31 | $2.26M 10-K · filed 2013-03-14 |
| 2010-12-31 | $2.30M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |